July 23, 2014 10:20 AM ET

Capital Markets

Company Overview of Mérieux Développement SAS

Executive Profile

Valerie Calenda Ph.D.

Executive Officer, Transgene SA
AgeTotal Calculated CompensationThis person is connected to 2 Board Members in 2 different organizations across 4 different industries.

See Board Relationships
49--

Background

Dr. Valerie Calenda, Ph.D. serves as a Partner at Mérieux Développement SAS. Dr. Calenda began her career at INSERM and then joined Transgene in 1994, where she was in charge of several R&D projects in HIV and Cardiovascular areas until 2000, when she led a spin-off project in cardio-vascular therapeutic area before working for a VC firm. She completed her training in Business Development at the PLG in UK and led the project management of Transgene’s HCV and HPV programs, ...

Corporate Headquarters

17 rue Bourgelat
Lyon, Rhône-Alpes 69002

France

Phone: 33 4 78 87 37 00
Fax: 33 4 78 87 37 02

Board Members Memberships

Director
2011-N/A
Former Director
2013-Present
Director

Education

Unknown/Other Education
Université d'Aix-Marseille II
PhD
Université d'Aix-Marseille II
BS
Université d'Aix-Marseille II

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
J. Joseph Kim Ph.D.Chief Executive Officer, President, Director and Member of Finance Committee
Inovio Pharmaceuticals, Inc.
$852.8K
Steven W. King Chief Executive Officer, President, Director, Chief Executive Officer of Avid Bioservices Inc and President of Avid Bioservices Inc
Peregrine Pharmaceuticals, Inc.
$445.8K
Stanley C. Erck Chief Executive Officer, President, Director and Member of Finance Committee
Novavax, Inc.
$448.3K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$535.6K
Eddie Gray Chief Executive Officer and Director
Dynavax Technologies Corporation
$533.3K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Mérieux Développement SAS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.